Nicholas J. Vogelzang

Nicholas J. Vogelzang
Nicholas J. Vogelzang, M.D.
Born December 13, 1949(1949-12-13)
Holland, Michigan
Alma mater University of Illinois School of Medicine
Occupation Oncologist
Employer Comprehensive Cancer Centers of Nevada
Known for Cancer research
Board member of Chair and medical director of the Developmental Therapeutics Committee and co-chair of the Genitourinary Committee for U.S. Oncology Research

Nicholas J. Vogelzang is a medical oncologist with Comprehensive Cancer Centers of Nevada (CCCN) and serves as chair and medical director of the Developmental Therapeutics Committee and Member of the Genitourinary Committee for US Oncology Research. His research interests include clinical trials for genitourinary malignancies and mesothelioma.

Contents

Career

Dr. Vogelzang joined Comprehensive Cancer Centers of Nevada in 2009 as a medical oncologist and serves as chair and medical director of the Developmental Therapeutic Committee and co-chair of the Genitourinary and Research Executive Committees for US Oncology Research.[1] Since 2004, he has been Head of the Genitourinary Oncology and Clinical Professor of Medicine for the University of Nevada School of Medicine in Las Vegas and Reno, Nevada.

He served as Director, Executive Vice President for Academic Affairs and Professor at Nevada Cancer Institute (NVCI) from 2004 to 2009.

During his tenure at the University of Chicago,he served as Professor of Medicine and Surgery (Urology) (1993 to 2003), Director for the University of Chicago Cancer Research Center (1999–2003), and was named the first Fred C. Buffett Professor in Medicine and Chair in Genitourinary Oncology (1999–2003).[2]

Dr. Vogelzang received his M.D. from the University of Illinois at Chicago in 1974. He completed his internship, residency and chief residency in internal medicine at Rush-Presbyterian-St. Luke's Medical Center in Chicago, followed by his fellowship in medical oncology at the University of Minnesota in Minneapolis. Vogelzang became the first editor of the Textbook of Genitourinary Oncology and remains the lead editor today.

Research

In 2002, Dr. Vogelzang directed the largest Phase II trial for mesothelioma using pemetrexed (brand name Alimta, by Eli Lilly). Pemetrexed is an antifolate, a class of drugs that targets the folic acid metabolic pathway. The results of the trial showed tumors shrank in 41 percent of patients on pemetrexed in combination with a more commonly used chemotherapy agent called cisplatin. Only 17 percent of patients receiving cisplatin alone experienced tumor shrinkage. Additionally, those on the pemetrexed combination lived nearly three months longer than those on cisplatin alone.[3][4]

Active research support

Dr. Vogelzang is actively involved in many research studies to test new therapies and treatments including:

  • A double-blind, randomised, multipled dose, Phase III, multicentre study of Alpharadin in the treatment of patients with symptomatic hormone refractory prostate cancer with skeletal metastases. The study began in October 2010 and is supported by Algeta USA.
  • A Phase 3, Randomized, Double-blind, Placebo-Controlled Study of Abiraterone Acetate (CB7630) Plus Prednisone in Patients with Metastatic Castration-Resistant Prostate Cancer Who Have Failed Docetaxel-Based Chemotherapy. The study began in March 2010 and is supported by Cougar Biotechnology.
  • A Phase 3, Randomized, Double-blind, Placebo-Controlled Study of Abiraterone Acetate (CB7630) Plus Prednisone in Asymptomatic or Mildly Symptomatic Patients with Metastatic Castration-Resistant Prostate Cancer. The study began in April 2009 and is supported by Cougar Biotechnology.
  • A Registry of Sipuleucel-T Therapy in men with advanced prostate Cancer. The study began in June 2010 and is supported by Dendreon.
  • A Phase 1/2., Open label, dose escalation, selected dose comparison trail of TOK-001 for the Treatment of Chemotherapy naïve castration resistant Prostate Cancer. The study began in September 2009 and is supported by Tokai.

Professional memberships

Dr. Vogelzang served on committees for the American Society of Clinical Oncology (ASCO), as well as its board of directors from 1993 to 1996, and is a former president of the Illinois Division of the American Cancer Society. Dr. Vogelzang was the principal investigator at the University of Chicago for Cancer and Leukemia Group B (CALGB) from 1988 to 1999, and chair of the CALGB Prostate Committee from 1993 to 1999.

He is a founding board member of the Mesothelioma Applied Research Foundation (MARF) and a member the American Association for Cancer Research, the American Urological Association, the Society of Urologic Oncology and the European Society for Medical Oncology. Dr. Vogelzang is the 2011 Chair-elect for the American Society of Clinical Oncology's (ASCO) Cancer Communications Committee, the current Vice Chair of the GU Committee and a member of the GU Translational Medicine Intergroup Committee for Southwest Oncology Group. For more than ten years, Dr. Vogelzang has served on the Medical and Scientific Advisory Boards for Us TOO, a prostate cancer education and support network for persons affected by prostate cancer.

Vogelzang is also a member of several medical societies including:

  • American Association of Cancer Research (AACR)
  • American College of Physicians (ACP)
  • American Society of Clinical Oncology (ASCO)
  • American Urological Association (AUA)
  • Chicago Urological Society (Honorary)
  • Clark County Medical Society
  • European Society for Medical Oncology (ESMO)
  • International Association for the Study of Lung Cancer (IASLC)
  • Kidney Cancer Association (KCA)
  • Mesothelioma Foundation (MARF)
  • Nevada Oncology Society (NOS)
  • Society of Urologic Oncology (SUO)

Corporate relationships

Dr. Vogelzang is a member of the scientific advisory board for Advanced Life Sciences, which is a biopharmaceutical company focused on the discovery, development and commercialization of novel drugs in the areas of infectious disease, inflammation and oncology.

Published works

  • Smith DC, Tangen CM, Hussain MHA, Van Veldhuizen, Jr PJ, Hartner GW, Stuart RK, Mills GM, Vogelzang NJ, Thompson IM. Phase II Evaluation of Early Oral Estramustine, Oral Etoposide and Intravenous Paclitaxel in Combination with Hormone Therapy in Patients with High-Risk Metastatic Adenocarcinoma of the Prostate. Southwest Oncology Group (SWOG) S0032 Urology 2011 Feb 18
  • Shapiro GI, Tibes R, Gordon MS, Wong BY, Eder JP, Borad MJ, Mendelson DS, Vogelzang NJ, Bastos BR, Weiss GJ, Fernandez C, Sutherland W, Sato H, Pierceall WE, Weaver D, Slough S, Wasserman E, Kufe DW, Von Hoff DD, Kawabe T, Sharma S: Phase I Studies of CBP501, a G2 Checkpoint Abrogator, as Monotherapy and in Combination with Cisplatin in Patients with Advanced Solid tumors. Clinical Cancer Res. 2011 January 10. (e-pub ahead of print)
  • Galsky MD, Hahn NM, Rosenberg J, Sonpavde S, Hutson T, Oh W, Dreicer R, Vogelzang NJ, Sternberg C, Bajorin D, Bellmunt D. Treatment of patients with metastatic urothelial cancer “unfit” for cisplatin-based chemotherapy. Journal of Clinical Oncology 2011 (IN PRESS)
  • Dorff TB, Flaig TW, Tangen C, Hussain M, Swanson GP, Wood, DP, Sakr W, Dawson NA, Haas NB, Crawford ED, Vogelzang NJ, Thompson I, Glode LM. “Adjuvant Androgen Deprivation for High Risk Prostate Cancer after Radical Prostatectomy: Southwest Oncology Group (SWOG) Study S9921”. Journal of Clinical Oncology 2010 322776 (IN PRESS)
  • Kris MG, Benowitz SI, Adams. S, Diller L, Ganz P, Kahlenberg MS, Le QT, Markman M, Masters GA, Newman L, Obel JC, Seidman AD, Smith SM, Vogelzang NJ, Petrelli NJ: Clinical Cancer Advances 2010: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology. Journal of Clinical Oncology, 2010 December 20;28(36):5327-47,. No abstract available
  • Khoury JD, Adcock DM, Chan F, Symanowski JT, Tiefenbacher S, Goodman O, Paz L, May, Ward DC, Vogelzang NJ, Fink LM. Increases in Quantitative D-Dimer Levels Correlate With Progressive Disease Better Than Circulating Tumor Cell Counts in Patients With Refractory Prostate Cancer. Am J Clin Pathol. 2010 Dec;134(6):964-969.PMID: 21088161 [PubMed - as supplied by publisher]
  • Vogelzang NJ. Another Step Toward the Cure of Metastatic Renal Cell Carcinoma? J Clin Oncol. 2010 Oct 25. [Epub ahead of print]
  • Picus J, Halabi S, Kelly WK, Vogelzang NJ, Whang YE, Kaplan EB, Stadler WM, Small EJ; for Cancer and Leukemia Group B. A phase 2 study of estramustine, docetaxel, and bbevacizumab in men with castrate-resistant prostate cancer: results from Cancer and Leukemia Group B Study 90006. Cancer. 2010 Sep 22. [Epub ahead of print]
  • Motzer RJ, Escudier B, Oudard S, Hutson TE, Porta C, Bracarda S, Grünwald V,Thompson JA, Figlin RA, Hollaender N, Kay A, Ravaud A; RECORD‐1 Study Group. Phase 3 trial of everolimus for metastatic renal cell carcinoma : final results and analysis of prognostic factors. Cancer. 2010 Sep 15;116(18):4256-65.PMID: 20549832 [PubMed - indexed for MEDLINE]Related citation
  • Sonpavde G, Sternberg CN, Rosenberg JE, Hahn NM, Galsky MD, Vogelzang NJ. Lancet Oncol. Second-line systemic therapy and emerging drugs for metastatic transitional-cell carcinoma of the urothelium. 2010 May 25. [Epub ahead of print]
  • Galsky MD, Vogelzang NJ. Ann Oncol. Docetaxel-based combination therapy for castration-resistant prostate cancer. 2010 Mar 29. [Epub ahead of print]
  • Leibowitz RL, Dorff TB, Tucker S, Symanowski J, Vogelzang NJ. BJU Int. Testosterone replacement in prostate cancer survivors with hypogonadal symptoms. 2010 May;105(10):1397-401. Epub 2009 Nov 11

In the media

Awards and Keynotes

Dr. Vogelzang has been recognized for his work by many of the leading medical groups and research organizations in the United States. Some of his notable honors include:

  • Received Everyday Hero Award from American Red Cross Las Vegas - October 2011
  • Named Healthcare Headliner by VEGAS Inc. magazine - October 2011
  • Awarded Gold Certificate of Excellence by National Cancer Institute - October 2011
  • Named Top Doctor by U.S. News & World Report - 2011
  • Honored with a service award for his more than 10 years on the board of the Mesothelioma Applied Research Foundation - June 2011
  • "Best Doctors in Las Vegas: Research" by Las Vegas Life - 2011
  • Schonfeld Memorial Lecture, Kidney Cancer Association 20th Anniversary meeting - Chicago, October 2010
  • Keynote Speaker, Japanese Society for Renal Cancer, 40th Anniversary - Tokyo, June 2010
  • Visiting Professor; Juravinski Cancer Center - Hamilton, Ontario, Canada - November 2008
  • “Best Doctors of Las Vegas,” by Las Vegas Woman Magazine - Las Vegas, October/November 2008
  • Annual award for distinguished volunteer at the Kidney Cancer Association’s Seventh International Kidney Cancer Symposium - Chicago, September 2008

References

  1. ^ http://www.cccnevada.com/cccn_abt_medteam_vogelzang.htm
  2. ^ http://chronicle.uchicago.edu/990715/vogelzang.shtml
  3. ^ http://www.mesotheliomaweb.org/pemetrexed.htm
  4. ^ http://www.ALIMTA.com

External links


Wikimedia Foundation. 2010.

Игры ⚽ Нужно решить контрольную?

Share the article and excerpts

Direct link
… Do a right-click on the link above
and select “Copy Link”